Key points are not available for this paper at this time.
Aflibercept in combination with FOLFIRI conferred a statistically significant survival benefit over FOLFIRI combined with placebo in patients with mCRC previously treated with oxaliplatin.
Cutsem et al. (Tue,) studied this question.